Home > Oncology > ASCO 2021 > Gynaecological Cancers > Novel drug combination for recurrent ovarian cancer

Novel drug combination for recurrent ovarian cancer

Presented By
Prof. David O’Malley, Ohio State University, OH, USA
ASCO 2021
Phase 1/2, FORWARD II
Mirvetuximab soravtansine, a folate receptor-targeting antibody-drug conjugate, in combination with bevacizumab, demonstrated impressive anti-cancer activity in the phase 1b FORWARD II trial. Mirvetuximab soravtansine is an antibody-drug conjugate comprising a folate receptor α (FRα)-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. Prior research showed that mirvetuximab soravtansine has encouraging anti-tumour activity in platinum-resistant ovarian cancer, either as monotherapy or in combination with bevacizumab [1,2]. As part of the phase 1b FORWARD II trial (NCT02606305), the combination of mirvetuximab soravtansine with bevacizumab was evaluated in patients with FRα-positive, platinum-agnostic ovarian cancer. This was defined as patients who had medium/high expression of FRα (≥50%/≥75% of cells with ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on